Supplements, Placebo, or Rosuvastatin Study

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 13% of the time (220 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-07-19. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 18.6% (raises risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: placebopriorriskenrollmentactive
  Phrases that lowered it: participantsrosuvastatincholesterolldlprescription
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Minimum age: 40 (lowers risk) · Who can join
• Blinding: triple (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 66 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 66.7% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 5.8% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 144402 (lowers risk) · Drug's FDA history
• Number of arms: 8 (lowers risk) · Design
• Drug's FAERS reports in the prior 12 months: 15069 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Drugs with FDA adverse-event history: 6 (lowers risk) · Drug's FDA history
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139) NCT00783263 · started 2008 · scored riskier than 12% of active trials completed
• Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) NCT01335997 · started 2011 · scored riskier than 23% of active trials terminated
• Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study NCT00728910 · started 2008 · scored riskier than 40% of active trials completed
• A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy NCT04669041 · started 2020 · scored riskier than 35% of active trials completed
• A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118) NCT01294683 · started 2011 · scored riskier than 14% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.